全文获取类型
收费全文 | 343385篇 |
免费 | 28717篇 |
国内免费 | 4121篇 |
专业分类
耳鼻咽喉 | 3786篇 |
儿科学 | 9232篇 |
妇产科学 | 9412篇 |
基础医学 | 94007篇 |
口腔科学 | 11609篇 |
临床医学 | 24925篇 |
内科学 | 54600篇 |
皮肤病学 | 11748篇 |
神经病学 | 18041篇 |
特种医学 | 10537篇 |
外国民族医学 | 75篇 |
外科学 | 44435篇 |
综合类 | 10893篇 |
现状与发展 | 19篇 |
一般理论 | 21篇 |
预防医学 | 6919篇 |
眼科学 | 3838篇 |
药学 | 10268篇 |
25篇 | |
中国医学 | 564篇 |
肿瘤学 | 51269篇 |
出版年
2023年 | 5963篇 |
2022年 | 8528篇 |
2021年 | 11005篇 |
2020年 | 10969篇 |
2019年 | 7995篇 |
2018年 | 9896篇 |
2017年 | 10081篇 |
2016年 | 10519篇 |
2015年 | 12100篇 |
2014年 | 21197篇 |
2013年 | 19214篇 |
2012年 | 15149篇 |
2011年 | 16184篇 |
2010年 | 16923篇 |
2009年 | 15911篇 |
2008年 | 12577篇 |
2007年 | 12824篇 |
2006年 | 11736篇 |
2005年 | 10931篇 |
2004年 | 9949篇 |
2003年 | 9436篇 |
2002年 | 9226篇 |
2001年 | 9243篇 |
2000年 | 8851篇 |
1999年 | 8384篇 |
1998年 | 5128篇 |
1997年 | 4292篇 |
1996年 | 4329篇 |
1995年 | 3764篇 |
1994年 | 3349篇 |
1993年 | 3097篇 |
1992年 | 6464篇 |
1991年 | 6350篇 |
1990年 | 6218篇 |
1989年 | 5865篇 |
1988年 | 5703篇 |
1987年 | 3092篇 |
1986年 | 1542篇 |
1985年 | 1981篇 |
1984年 | 1909篇 |
1983年 | 1674篇 |
1982年 | 1585篇 |
1981年 | 1389篇 |
1980年 | 1319篇 |
1979年 | 1251篇 |
1978年 | 1182篇 |
1977年 | 943篇 |
1976年 | 847篇 |
1974年 | 870篇 |
1973年 | 849篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
101.
102.
《Transplantation proceedings》2022,54(10):2818-2821
BackgroundGraft-vs-host disease (GVHD) is a common complication of allogeneic hematopoietic stem cell transplant. Myopathy is a rare neuromuscular sign of chronic GVHD, with an incidence of less than 4% in all patients. The data are heterogeneous, and no standard criteria exists for diagnosis or treatment.Case ReportWe present the case of an 18-year-old man with acute lymphoblastic leukemia, who developed myopathy associated with GVHD 19 months after allogeneic hematopoietic stem cell transplant from an unrelated donor. The patient had a previous history of acute cutaneous and chronic hepatic GVHD. At the time of symptom onset, the immunosuppressive drugs were tapered. He developed with sudden symmetrical proximal muscle weakness that prevented him from walking. Diagnosis was confirmed using magnetic resonance imaging, electromyography, muscle enzymes, and muscle biopsy results. He initially responded to immunosuppressive therapy but relapsed after quick tapering of prednisone, requiring a prolonged course of steroids and an additional dose of immune globulin intravenous. At the moment of the publication, the patient has 9 months free from GVHD relapse.ConclusionsGVHD-associated myopathy is a rare complication of hematopoietic stem cell transplant and must be suspected in patients with sudden proximal muscle weakness and moderate pain. Diagnosis is challenging and must include magnetic resonance imaging, electromyography, muscle enzymes, and muscle biopsy results. Usually, all patients respond adequately to immunosuppression. 相似文献
103.
104.
105.
106.
《European journal of surgical oncology》2019,45(6):931-940
BackgroundIsolated local recurrent or persistent esophageal cancer (EC) after curative intended definitive (dCRT) or neoadjuvant chemoradiotherapy (nCRT) with initially omitted surgery, is a potential indication for salvage surgery. We aimed to evaluate safety and efficacy of salvage surgery in these patients.Material and methodsA systematic literature search following PRISMA guidelines was performed using databases of PubMed/Medline. All included studies were performed in patients with persistent or recurrent EC after initial treatment with dCRT or nCRT, between 2007 and 2017. Survival analysis was performed with an inverse-variance weighting method.ResultsOf the 278 identified studies, 28 were eligible, including a total of 1076 patients. Postoperative complications after salvage esophagectomy were significantly more common among patients with isolated persistent than in those with locoregional recurrent EC, including respiratory (36.6% versus 22.7%; difference in proportion 10.9 with 95% confidence interval (CI) [3.1; 18.7]) and cardiovascular complications (10.4% versus 4.5%; difference in proportion 5.9 with 95% CI [1.5; 10.2]). The pooled estimated 30- and 90-day mortality was 2.6% [1.6; 3.6] and 8.0% [6.3; 9.8], respectively. The pooled estimated 3-year and 5-year overall survival (OS) were 39.0% (95% CI: [35.8; 42.2]) and 19.4% [95% CI:16.5; 22.4], respectively. Patients with isolated persistent or recurrent EC after initial CRT had similar 5-year OS (14.0% versus 19.7%, difference in proportion −5.7, 95% CI [-13.7; 2.3]).ConclusionsSalvage surgery is a potentially curative procedure in patients with locally recurrent or persistent esophageal cancer and can be performed safely after definitive or neoadjuvant chemoradiotherapy when surgery was initially omitted. 相似文献
107.
IntroductionWith the increasing reliance on targeted therapies and immunotherapy, no standard management strategy is today available for the treatment of locally, distant, or both renal cell carcinoma (RCC) recurrences, and their surgical treatment seems to play a crucial role. We report the 20-year experience of our center evaluating the short- and long-term outcomes of patients undergone surgical resection of RCC recurrences, and the possible role of repeated surgical resections of RCC recurrences.Materials and methodsFrom January 1999 to January 2019, 40 patients underwent surgical resection of isolated locally recurrent RCC (iLR-RCC-group), locally recurrent RCC associated with the presence of distant recurrence (LR-DR-RCC-group), and distant-only recurrent RCC (DR-RCC-group). Data regarding pre-, intra-, post-operative course, and follow-up, prospectively collected in an institutional database, were retrospectively analyzed and compared.ResultsiLR-RCC-group was composed of 9 patients, LR-DR-RCC-group of 6 patients, and DR-RCC-group of 25 patients. The recurrence rate was 55.6% (5/9 patients) in iLR-RCC-group, 50% (3/6 patients) in LR-DR-RCC-group, and 44% (11/25) patients in DR-RCC-group, p = 0.830. 3/5 (60%) patients in iLR-RCC-group, 2/3 (66.7%) patients in LR-DR-RCC-group, and 7/11 (63.6%) patients in DR-RCC group underwent to almost one further local treatments of their recurrences, respectively (p = 0.981). No differences in the mean disease-free survival (p = 0.384), overall survival (OS) (p = 0.881), and cancer-specific survival (p = 0.265) were reported between the three groups. In DR-RCC-group, patients who underwent further local treatments of new recurrences presented a longer OS: 150.7 versus 66.5 months (p = 0.004).ConclusionsA surgical resection of RCC recurrences should be always taken in consideration, also in metastatic patients and/or in those who have already undergone surgery of previous RCC recurrence, whenever radicality is still possible, because this approach may offer a potentially long survival. 相似文献
108.
109.
110.